Trophos

42 articles about Trophos

• 

  Biotech Movers and Shakers Aug. 27

  8/27/2018

  Who made a splash in the biotech world this week? Here are some notable people.

• Buying Spree Continues as Roche Picks Up Trophos in $540 Million Deal

  1/19/2015

• Trophos Completes Pivotal Phase II/III Study of Olesoxime in Spinal Muscular Atrophy (SMA)

  11/6/2013

• Trophos Announces Final Patient Completion of Phase II Proof-of-Concept Study of TRO40303 in Patients Treated for Acute Myocardial Infarction

  10/2/2013

• Trophos Completes Patient Enrolment in a First Study of Olesoxime in Relapsing Remitting Multiple Sclerosis

  8/7/2013

• Trophos Launches First Study of Olesoxime in Multiple Sclerosis Patients

  3/14/2013

• Trophos Announces Positive Interim Review in Pivotal Study of Olesoxime in Spinal Muscular Atrophy

  2/28/2013

• Trophos Program Boosted by EUR 1 Million Grant for Olesoxime in Progressive Multiple Sclerosis

  10/11/2012

• Marceline Clementine Appointed Chief Financial Officer of Trophos

  9/18/2012

• Trophos Announces Conclusion of MitoTarget Consortium, Achieving Advanced Understanding of Neurodegenerative Diseases

  7/31/2012

• Trophos Appoints JSB-Partners as Global Partnership Advisor

  7/23/2012

• Trophos Appoints Christine Placet as Chief Executive Officer

  6/12/2012

• Actelion Ltd. Pulls Out of $250 Million Trophos Buy After ALS Drug Failure

  12/15/2011

• Trophos Initiates Phase II Proof of Concept Study for Novel Cardioprotective Compound, TRO40303, in Acute Myocardial Infarction

  10/31/2011

• Trophos Hosts Round-Table Meetings at ECTRIMS to Design POC Trial to Treat Progression in Multiple Sclerosis

  10/25/2011

• Trophos Announces Final Patient Completion of Pivotal Phase 3 Efficacy Study of Olesoxime in Amyotrophic Lateral Sclerosis (ALS, Or Lou Gehrig's Disease)

  9/22/2011

• Trophos Completes Patient Enrolment in Pivotal Efficacy Study of Olesoxime in Spinal Muscular Atrophy

  9/8/2011

• Trophos Awarded Key US Patent Covering Use of Novel Cardioprotective Compound, TRO40303

  8/23/2011

• Trophos Presents Results Data at the American Academy of Neurology on SMA and MS

  4/15/2011

• Trophos Successfully Completes Phase 1 Study for Novel Cardioprotective Compound, TRO40303

  2/24/2011